Regulus Therapeutics Inc. (RGLS)
$0.31
+0.03 (+12.52%)
Rating:
Recommendation:
Buy
| Symbol | RGLS |
|---|---|
| Price | $0.31 |
| Beta | 2.204 |
| Volume Avg. | 2.24M |
| Market Cap | 45.254M |
| Shares () | - |
| 52 Week Range | 0.16-1.48 |
| 1y Target Est | - |
| DCF Unlevered | RGLS DCF -> | |
|---|---|---|
| DCF Levered | RGLS LDCF -> | |
| ROE | -67.08% | Strong Sell |
| ROA | -46.76% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 23.85% | Neutral |
| P/E | - | |
| P/B | 0.92 | Buy |
Latest RGLS news
About
Download (Excel)Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.